Novel Therapeutic Agent for Pediatric Cancer Developed at UC San Diego in Clinical Trials

OPACC
Aug 12, 2015
1 min read

Donald L. Durden, MD, PhD, pediatric researcher at University of California, San Diego School of Medicine and Moores Cancer Center has identified and developed a novel therapeutic target for neuroblastoma, the second most common solid-tumor childhood cancer.

Comments

Finding the balance between efficacy and toxicity in pediatric cancer treatment

Study finds evidence for repurposing thiostrepton as an anti-rhabdomyosarcoma drug

FDA Grants Rare Pediatric Designation for Iopofosine-131 in Glioma Subset

‘Switch’ could turn off growth of tough childhood cancer

Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing

Higher levels of HIF2α found to slow down aggressive childhood cancer

University of Minnesota study uncovers new genetic factors in childhood leukemia

Survivors of high-risk neuroblastoma face substantial late effects of modern therapies

Researchers develop a new approach for treating children with neuroblastoma

Pesticides used near farm communities tied to rare but deadly childhood cancer

Recent Posts